Pharmaceutical News

RSS

MediciNova starts phase II clinical trial of MN-166 for multiple sclerosis

MediciNova today announced the enrollment of patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. MN-166 is an orally administered drug with a novel mechanism of action that includes the inhibition of phosphodiesterase IV.

2 Aug 2005

Heparinase I is not a suitable replacement for protamine

The results of an international clinical trial led by Duke University Medical Center researchers has shown that a new drug is not a suitable replacement for protamine, a drug that has been used for more than 40 years after coronary artery bypass surgery to return thinned blood to its normal state.

1 Aug 2005

FDA bans antibiotic use for poultry

The U.S. Food and Drug Administration (FDA) has banned the use of a poultry antibiotic made by Bayer.

31 Jul 2005

Law to restrict cold medicines well on it's way

A bill that would limit access to common cold medicines containing pseudoephedrine, an ingredient that can be used to make the highly addictive drug methamphetamine, has been unanimously approved by the Senate judiciary committee.

29 Jul 2005

Ranbaxy receives tentative approval to manufacture and market Glimepiride tablets

Indian drug manufacturer, Ranbaxy Pharmaceuticals has tentative approval from the U.S. Food and Drug Administration to manufacture and market Glimepiride Tablets, 3 mg and 6 mg.

28 Jul 2005

Pharmaceutical direct-to-consumer to evolve holistically

Restrictions against using brand names have rendered pharmaceutical Direct-to-Consumer Advertising (DTCA) in Europe an informative rather than promotional exercise. DTCA is now broadening its scope, evolving from its narrow publicity orientation to a more comprehensive approach focused on improved patient outcomes and value addition.

27 Jul 2005

Biota's potential damages claim against GlaxoSmithKline could be as high as $430 million

Biota Holdings Limited of Melbourne, Australia, has announced its Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support Biota’s influenza drug, Relenza. The damages assessment was filed with the Victorian Supreme Court and estimates Biota’s losses in the range of $308 million to $430 million.

26 Jul 2005

TEVA to acquire IVAX for $7.4 billion

TEVA Pharmaceutical Industries and IVAX Corporation have jointly announced that they have signed a definitive agreement providing for the acquisition of IVAX by TEVA.

26 Jul 2005

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

26 Jul 2005

Government in Ontario will pay for three new cancer drugs

Canadian Health Minister George Smitherman has announced that the government will add three new and expensive cancer-fighting drugs to the list of medications it funds.

25 Jul 2005

Breast cancer drug Herceptin soon to be widely available on NHS

The British health secretary Patricia Hewitt has ordered a fast-track assessment of Herceptin, a drug which has shown great promise in treating the early stages of breast cancer.

23 Jul 2005

Provectus to begin clinical trials of new cancer treatment, PV-10

Provectus Pharmaceuticals announced today that it has obtained final clearance to begin the first Phase 1 clinical trial of PV-10, the Company's lead cancer treatment.

21 Jul 2005

ev3 announces FDA approval of treatment for brain vascular disorder

ev3 today announced that its majority-owned subsidiary Micro Therapeutics has received pre-market application (PMA) approval from the U.S. Food and Drug Administration (FDA) to commercialize its Onyx Liquid Embolic System (Onyx) for the treatment of arterio-venous malformations (AVMs), a vascular disorder in the brain.

21 Jul 2005

Sale of abortion-pill threatened by U.S. lawmakers

The U.S. Food and Drug Administration (FDA) has issued a new warning this week regarding the abortion pill RU-486 following the deaths of five women taking it, from bacterial infections.

21 Jul 2005

UK medical watchdog wants more proof on value of Alzheimer's drugs

In the UK the country's watchdog for cost-effectiveness in medical treatments, the National Institute for Health and Clinical Excellence (NICE), has asked drug makers for more evidence about the benefits of their Alzheimer's medicines.

21 Jul 2005

Sanofi pasteur gear up for influenza pandemic with new plant

Work has officially begun on the construction of a new sanofi pasteur manufacturing facility that will expand the ability of the United States to produce influenza vaccine for both routine influenza immunization and in case of a global influenza pandemic.

21 Jul 2005

New program will help fill a drug-discovery void as pharmaceutical companies have largely abandoned natural products research

The natural world has been medicine's most effective arsenal, providing life-saving antibiotics and our most potent anti-cancer drugs.

20 Jul 2005

U.S. stockpile of anti-flu drugs is "totally inadequate"

The United States does not have nearly enough antiviral drugs on hand to fight a coming influenza pandemic, according to the Infectious Diseases Society of America (IDSA).

19 Jul 2005

Results demonstrate the safety and tolerability of ABthrax treatment for Anthrax infection

Human Genome Sciences has announced that results published in the current issue of Clinical Infectious Diseases demonstrate that the first investigational agent against anthrax infection to be evaluated in a clinical study since the 2001 anthrax attacks in the United States, is safe, well tolerated and achieves the blood levels predicted by relevant animal models as necessary to afford significant protection from the lethal effects of the anthrax toxin

19 Jul 2005

Discount injectables bought offshore not worth the price

The American Society for Aesthetic Plastic Surgery (ASAPS) has announced that patients need to be wary of “bargain” injectables or other treatments that are not approved by the United States Food and Drug Administration (FDA). Unregulated injectables or treatments can compromise patient health and put patient lives at risk.

19 Jul 2005